Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
- In the first presentation of long-term data for UCB?s investigational molecule bimekizumab, late-breaking results from the Phase 2b BE ACTIVE study showed promising response rates that increased up to Week 24 and were maintained to Week 48 across disease manifestations in psoriatic arthritis
- Findings continue to underscore the potential value of bimekizumab?s unique dual neutralization of IL-17A and IL-17F
- Results presented today as part of late-breaking oral session at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting